Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

BACKGROUND: Bruton’s tyrosine kinase (BTK) is a key signaling node in B cell receptor (BCR) and Fc receptor (FcR) signaling. BTK inhibitors (BTKi) are an emerging oral treatment option for patients suffering from multiple sclerosis (MS). Remibrutinib (LOU064) is a potent, highly selective covalent B...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuesslein-Hildesheim, Barbara, Ferrero, Enrico, Schmid, Cindy, Huck, Catherine, Smith, Paul, Tisserand, Sarah, Rubert, Joelle, Bornancin, Frederic, Eichlisberger, Denis, Cenni, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463946/
https://www.ncbi.nlm.nih.gov/pubmed/37633912
http://dx.doi.org/10.1186/s12974-023-02877-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463946/
https://www.ncbi.nlm.nih.gov/pubmed/37633912
http://dx.doi.org/10.1186/s12974-023-02877-9

Ejemplares similares